Study of 99 million vaccinated individuals confirms pre-established safety signals for myocarditis, pericarditis, Guillain-Barré syndrome, and cerebral venous sinus thrombosis
Since declaration of the COVID-19 pandemic by the World Health Organization (WHO) on March 11, 2020 more than 13.5 billion doses of COVID-19 vaccines have been administered worldwide; and as of November 2023, at least 70.5 % of the world’s population had received at least one dose of a COVID-19 vaccine.
This study was a multi-country analysis that confirmed pre-established safety signals for myocarditis, pericarditis, Guillain-Barré syndrome, and cerebral venous sinus thrombosis. Other potential safety signals that require further investigation were also identified.
COVID-19 vaccine linked to possible health issues, study finds - NEWS NATION
SOURCE STUDY ...
BACKGROUND ...
Clinical Considerations: Myocarditis after COVID-19 Vaccines | CDC
Investigating Long-Term Effects of Myocarditis | CDC
GBS (Guillain-Barré Syndrome) and Vaccines | Vaccine Safety | CDC
Search Results | CDC - cerebral venous sinus thrombosis
REFERENCE ...
Heart Inflammation - Myocarditis | NHLBI, NIH
Heart Inflammation - Pericarditis | NHLBI, NIH
Guillain-Barré Syndrome | Campylobacter | CDC
cerebral venous sinus thrombosis - Search Results Search Results - NIH/NHLBI